摘要
目的探讨吡非尼酮治疗特发性肺纤维化的临床效果。方法选取我院2015年2月至2018年2月收治的特发性肺纤维化患者110例,根据随机数字表法将其分为对照组与观察组,各55例。两组均给予常规对症治疗,对照组加用甲泼尼龙片,观察组加用吡非尼酮,两组均治疗36周。比较两组治疗效果。结果观察组治疗总有效率为89.09%,高于对照组的74.55%,差异具有统计学意义(P<0.05)。治疗后,两组患者FEV1、FVC、DLco、MMEF水平均升高,且观察组FEV1、FVC、MMEF水平高于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者DLco水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者血清IL-6、IL-12、IL-18水平均改善,且观察组优于对照组,差异具有统计学意义(P<0.05)。观察组不良反应总发生率为9.09%,与对照组的3.64%比较,差异无统计学意义(P>0.05)。结论与常规治疗相比,吡非尼酮治疗特发性肺纤维化能进一步改善患者的肺部功能,并降低炎症因子水平,且不良反应少,临床价值较高,值得推广与应用。
Objective To explore the clinical effect of pifenidone in the treatment of idiopathic pulmonary fibrosis.Methods A total of 110 patients with idiopathic pulmonary fibrosis admitted in our hospital from February 2015 to February 2018 were selected and divided into control group and observation group according to random number table method,with 55 cases in each group.Both groups were given routine symptomatic treatment.The control group was given methylprednisolone tablets,while the observation group was given pifenidone.Both groups were treated for 36 weeks.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was 89.09%,which was higher than 74.55%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of FEV1,FVC,DLco and MMEF in the two groups increased,and the levels of FEV1,FVC and MMEF in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in DLco level between the two groups after treatment(P>0.05).After treatment,the levels of serum IL-6,IL-12 and IL-18 in the two groups improved,and those in the observation group were better than the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 9.09%,and which compared with 3.64%in the control group,the difference was not significant(P>0.05).Conclusion Compared with conventional therapy,pifenidone can further improve pulmonary function and decrease the levels of inflammation factors in patients with idiopathic pulmonary fibrosis,with fewer adverse reactions and higher clinical value,which is worthy of promotion and application.
作者
王粉利
付伟
李健
李彦斌
WANG Fen-li;FU Wei;LI Jian;LI Yan-bin(Changqing Oilfield Staff Hospital,Xi'an 710201,China)
出处
《临床医学研究与实践》
2019年第9期32-34,共3页
Clinical Research and Practice
关键词
特发性肺纤维化
吡非尼酮
肺功能
炎症因子
不良反应
idiopathic pulmonary fibrosis
pirfenidone
pulmonary function
inflammatory factor
adverse reaction
